Clinical Genomics, father and son embrace, blood cancer

Oncology | Blood Cancer

Find the answers with our blood cancer biomarker solutions

Validated and custom biomarker assays for hematologic malignancies

Biomarker testing is key in hematologic malignancies such as chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs). QIAGEN has a wide range of molecular testing solutions for research and diagnostics, including validated, IVD qPCR assays and research solutions with NGS and dPCR.

Whether you are a clinical researcher or diagnostic lab professional, explore our blood biomarker testing solutions by biomarker or disease to find the right assay for your workflow.

What is blood cancer?

Blood cancer is an overarching term for cancers affecting the blood, bone marrow and lymphatic system. Other terms for blood cancer are hematological cancer and hematological malignancies. Blood cancer typically starts in the bone marrow, where blood is produced.

What are the types of blood cancer?

There are over 100 different types of blood cancer – including leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) – and the key genes implicated in each type vary. This makes it impossible to have a single technology solution or approach to blood cancer care. But by closely examining the role of various signaling pathways and targeting specific steps in those pathways, we can identify specific molecular markers for each blood cancer type.

What are the key biomarkers in blood cancer?

Important genes include JAK2, CALR, and BCR::ABL1 Mbcr. Learn more about the biomarkers involved in blood cancer.

How can you detect and monitor blood cancer biomarkers?

Multiple technologies can be used to detect and monitor biomarkers in oncohematology, including next-generation sequencing, quantitative real-time PCR and digital PCR. Discover which of our workflows can support your blood cancer work.

Find testing solutions by blood cancer biomarker or disease

Find what you need easily, whether you want to study a specific gene, use a particular technology or learn more about a specific blood cancer type.

Explore by gene

Dive deeper into some of the genes commonly associated with blood cancer with our blood cancer biomarker assays.

Biomarker assays
JAK2 V617F	CALR	BCR::ABL1 Mbcr
BCR::ABL1 mbcr	MPL W515L/K	NPM1
NPM1 mut A	NPM1 mut B&D	PML::RARA bcr 1
PML::RARA bcr 2	PML::RARA bcr 3	CBFB::MYH11 A
RUNX1::RUNX1T1	WT1	ETV6::RUNX1

Workflows for blood cancer research and hematological malignancies

We support your clinical blood cancer care and molecular research with a comprehensive assay, platform and service portfolio. In addition, we have broad expertise in IVD development and global regulatory and commercialization capabilities – making us the trusted partner for your blood cancer companion diagnostics.

A comprehensive, integrated oncohematology workflow.

QIAseq products are intended for non-clinical applications. These products are not intended for the diagnosis, prevention or treatment of a disease.

Product-specific disclaimers can be found on the respective product pages.

Shifting the paradigm in oncohematology clinical testing using digital PCR

Digital PCR is changing the game in oncology clinical testing and diagnostics. It does this by offering clinicians high precision testing in a low footprint PCR workflow, and is characterized by:

Diagnostic precision^* and accuracy
Use for monitoring patients' response to therapy
Use for testing from tissue and liquid biopsy samples
High precision^*and inhibitor tolerance that's well adapted for liquid biopsy samples with low ctDNA/RNA concentration

A diagnostic test method is described as precise when repeated analyses on the same sample give similar results

Explore clinical testing

What are the latest advances in blood cancer research?

Watch our most recent webinars to learn how experts have successfully incorporated multiple technologies from one partner to personalize blood cancer care. Plus, get the latest insights on our oncohematology assays, platforms and services.

Where are our oncohematology and cancer research solutions used?

Blood cancer experts worldwide are transforming diagnostics and research. Quest Diagnostics uses QCI Precision Insights to return 70% of NGS cases within minutes, UK hospitals test JAK2 and CALR from a single blood sample, and Belgian scientists rely on QIAseq panels for 100% coverage of GC-rich AML genes. Read the case studies and be inspired by blood cancer experts and labs from around the world.

Disclaimers:

QIAcuity Digital PCR instruments are sold under license from Bio-Rad Laboratories, Inc. and exclude rights for use with pediatric applications.

Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.